About
16
Publications
9,264
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1,253
Citations
Introduction
Current institution
Additional affiliations
April 2016 - present
October 2012 - March 2016
January 2009 - September 2012
Education
January 2020 - December 2021
January 2007 - March 2009
January 2005 - December 2006
Publications
Publications (16)
Rifampicin was discovered in 1965 and remains one of the most important drugs in tuberculosis treatment that is valued for its sterilizing activity and ability to shorten treatment. Antimicrobial activity of rifampicin was initially proved in vitro; subsequently numerous in vivo studies showed the bactericidal properties and dose-dependent effect o...
Objectives:
Limited data exist on clinical associations and genotypic correlates of linezolid resistance in Mycobacterium tuberculosis. We aimed to describe mutations and clinical factors associated with phenotypic linezolid resistance from patients with drug-resistant TB at two public sector facilities in South Africa.
Methods:
Adults and adole...
Tuberculosis (TB) remains a global health concern, despite availability of antituberculosis drugs. Drug-resistant Mycobacterium tuberculosis strains were identified shortly after the discovery and introduction of streptomycin for the treatment of this disease. Subsequently, multidrug therapy was implemented for TB treatment; however, this was soon...
Background:
Whole genome sequencing has revolutionised the interrogation of mycobacterial genomes. Recent studies have reported conflicting findings on the genomic stability of Mycobacterium tuberculosis during the evolution of drug resistance. In an age where whole genome sequencing is increasingly relied upon for defining the structure of bacter...
The emergence of drug resistance continues to plague TB control, with a global increase in the prevalence of MDR-TB. This acts as a gateway to XDR-TB and thus emphasizes the urgency for drug development and optimal treatment options. Bedaquiline is the first new anti-TB drug approved by the FDA in 40 years and has been shown to be an effective trea...
The inherent drug susceptibility of microorganisms is determined by multiple factors, including growth state, the rate of
drug diffusion into and out of the cell, and the intrinsic vulnerability of drug targets with regard to the corresponding
antimicrobial agent. Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), remains a signi...
Central dogma suggests that rifampicin resistance in Mycobacterium tuberculosis develops solely through rpoB gene mutations.
To determine whether rifampicin induces efflux pumps activation in rifampicin resistant M. tuberculosis strains thereby defining rifampicin resistance levels and reducing ofloxacin susceptibility.
Rifampicin and/or ofloxacin...
Since the discovery of the tubercle bacillus by Robert Koch in 1882(110), a greater understanding of the dynamics and survival mechanisms of this pathogen has led to more questions than answers. ...
Anti-tuberculosis drugs are a two-edged sword. While they destroy pathogenic M. tuberculosis they also select for drug resistant bacteria against which those drugs are then ineffective. Global surveillance has shown that drug resistant Tuberculosis is widespread and is now a threat to tuberculosis control programs in many countries. Application of...
To determine the extent of pyrazinamide (PZA) resistance in isolates from previously treated patients from the Western Cape, South Africa.
Drug-resistant isolates, isolates resistant to one or more drugs other than PZA (PZA resistance is not routinely determined) (n = 127), and drug-susceptible (n = 47) clinical isolates of Mycobacterium tuberculos...
